Efficacy, effectiveness and safety of the adjuvanted influenza vaccine in the population aged 65 or over
-
Published:2023-04-20
Issue:4
Volume:36
Page:334-345
-
ISSN:0214-3429
-
Container-title:Revista Española de Quimioterapia
-
language:
-
Short-container-title:Rev Esp Quimioter
Author:
Arrazola Martínez María Pilar,Eiros Bouza José María,Plans Rubió Pere,Puig-Barberà Joan,Ruiz Aragón Jesús,Torres Lana Álvaro
Abstract
Most of the complications and deaths related to seasonal flu occur in the elderly population (≥65 years) with comorbidities, and the influenza vaccine is the most effective way to prevent them. Immunization is less effective in older adults due to immunosenescence. MF59-adjuvanted vaccines, designed to improve the magnitude, persistence and amplitude of the immune response in elderly people, have been used in clinical practice since 1997 in their trivalent formulation and, since 2020, in their tetravalent formulation. Data from various studies show that these vaccines are not only safe for all age groups, with a reactogenicity profile similar to that of the conventional vaccine, but also that they are especially effective in boosting the immune response in the population aged 65 or over by increasing antibody titers after vaccination and significantly reducing the risk of hospital admission. Adjuvanted vaccines have been shown to provide cross-protection against heterologous strains and to be as effective as the high-dose vaccine in the population aged 65 or over. In this review, the scientific evidence on the efficacy and effectiveness of the MF59-adjuvanted vaccine in real clinical practice in people ≥65 years of age is analyzed through a narrative and descriptive review of the literature with data from clinical trials, observational studies and systematic reviews or meta-analysis.
Publisher
Sociedad Espanola de Quimioterapia
Subject
Microbiology (medical),Pharmacology,General Medicine